Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in sweden 2003-2010

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Karlsson, Annika ^a   Björkman, Per ^b   Bratt, Göran ^c   Ekvall, Håkan ^d   Gisslén, Magnus ^e   Sönnerborg, Anders ^a,f   Mild, Mattias ^a,g   Albert, Jan ^a,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d SUNDSVALL HOSPITAL   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Swedish Institute for Communicable Diseases   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; EUROPEAN UNION; FEMALE; GENE CLUSTER; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MULTIDRUG RESISTANCE; NONHUMAN; PHYLOGENY; SEQUENCE HOMOLOGY; SWEDEN; TRANSMITTED DRUG RESISTANCE; TREND STUDY; VIRUS DIAGNOSIS; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS TYPING; CLASSIFICATION; DISEASE TRANSMISSION; DRUG EFFECT; GENETICS; HOMOSEXUALITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PREVALENCE; TIME; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; PHYLOGENY; POLYMERASE CHAIN REACTION; PREVALENCE; RNA, VIRAL; SWEDEN; TIME FACTORS; YOUNG ADULT;

EID: 84858680178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033484     Document Type: Article

References (39)

1. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, et al. (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11: 363-371.
2. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF, (2008) The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 13 (Suppl 2): 1-13.
3. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF, (2008) Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13 (Suppl 2): 25-36.
4. Josephson F, Albert J, Flamholc L, Gisslen M, Karlström O, et al. (2009) Treatment of HIV infection: Swedish recommendations 2009. Scand J Infect Dis 41: 788-807.
5. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, et al. (2008) Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 47: 266-285.
6. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, et al. (2011) European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 13: 77-108.
7. UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study; UK Register of HIV Seroconverters (2007) Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 21: 1035-1039.
8. Yerly S, von Wyl V, Ledergerber B, Boni J, Schupbach J, et al. (2007) Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21: 2223-2229.
9. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, et al. (2010) Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One 5: e12718.
10. Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, et al. (2010) Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 65: 2620-2627.
11. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, et al. (2010) Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 24: 1203-1212.
12. Audelin AM, Gerstoft J, Obel N, Mathiesen L, Laursen A, et al. (2011) Molecular Phylogenetics of Transmitted Drug Resistance in Newly Diagnosed HIV Type 1 Individuals in Denmark, a Nation-Wide Study. AIDS Res Hum Retroviruses.
13. SPREAD programme. (2008) Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22: 625-635.
14. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, et al. (2009) Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200: 1503-1508.
15. Sönnerborg A, Johansson B, Ayehunie S, Julander I, (1993) Transmission of zidovudine-resistant HIV-1. AIDS 7: 1684-1685.
16. Maljkovic I, Wilbe K, Sölver E, Alaeus A, Leitner T, (2003) Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01_AE. AIDS Res Hum Retroviruses 19: 989-997.
17. Lindström A, Ohlis A, Huigen M, Nijhuis M, Berglund T, et al. (2006) HIV-1 transmission cluster with M41L 'singleton' mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men. Antivir Ther 11: 1031-1039.
18. Murillo W, de Rivera IL, Parham L, Jovel E, Palou E, et al. (2010) Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med 11: 95-103.
19. Pandit A, Mackay WG, Steel C, van Loon AM, Schuurman R, (2008) HIV-1 drug resistance genotyping quality assessment: results of the ENVA7 Genotyping Proficiency Programme. J Clin Virol 43: 401-406.
20. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724.
21. Gifford RJ, Liu TF, Rhee SY, Kiuchi M, Hue S, et al. (2009) The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 25: 1197-1198.
22. Hall TA, (1999) BioEdit: a user-friendly biological sequence alignment editor and analysisprogram for Windows 95/98/NT. Nucl Acids Symp Ser 41: 95-98.
23. Guindon S, Gascuel O, (2003) A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52: 696-704.
24. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, et al. (2010) New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59: 307-321.
25. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
26. Alizon S, von Wyl V, Stadler T, Kouyos RD, Yerly S, et al. (2010) Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog 6: e1001123.
27. Kouyos RD, von Wyl V, Yerly S, Boni J, Taffe P, et al. (2010) Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis 201: 1488-1497.
28. Skar H, Axelsson M, Berggren I, Thalme A, Gyllensten K, et al. (2011) Dynamics of two separate but linked HIV-1 CRF01_AE outbreaks among injection drug users in Stockholm, Sweden, and Helsinki, Finland. J Virol 85: 510-518.
29. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2010) Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 18: 156-163.
30. Sungkanuparph S, Oyomopito R, Sirivichayakul S, Sirisanthana T, Li PC, et al. (2011) HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis 52: 1053-1057.
31. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921-929.
32. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092-2098.
33. Attia S, Egger M, Muller M, Zwahlen M, Low N, (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: 1397-1404.
34. Yebra G, de Mulder M, Perez-Elias MJ, Perez-Molina JA, Galan JC, et al. (2011) Increase of Transmitted Drug Resistance among HIV-Infected Sub-Saharan Africans Residing in Spain in Contrast to the Native Population. PLoS One 6: e26757.
35. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, et al. (2011) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11: 750-759.
36. Yerly S, Junier T, Gayet-Ageron A, Amari EB, von Wyl V, et al. (2009) The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 23: 1415-1423.
37. Booth CL, Geretti AM, (2007) Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-1056.
38. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305: 1327-1335.
39. Frentz D, van de Vijver DA, Boucher CA, Albert J, (2011) Estimates of HIV transmitted drug resistance can be inflated due to natural sequence polymorphisms. J Acquir Immune Defic Syndr 58: e135-137.